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A new generation of artificial proteins, derived from alpha-helicoidal HEAT-like repeat protein scaffolds 
(αRep), was previously characterized as an effective source of intracellular interfering proteins. In 
this work, a phage-displayed library of αRep was screened on a region of HIV-1 Gag polyprotein 
encompassing the C-terminal domain of the capsid, the SP1 linker and the nucleocapsid. This region is 
known to be essential for the late steps of HIV-1 life cycle, Gag oligomerization, viral genome packaging 
and the last cleavage step of Gag, leading to mature, infectious virions. Two strong αRep binders 
were isolated from the screen, αRep4E3 (32 kDa; 7 internal repeats) and αRep9A8 (28 kDa; 6 internal 
repeats). Their antiviral activity against HIV-1 was evaluated in VLP-producer cells and in human SupT1 
cells challenged with HIV-1. Both αRep4E3 and αRep9A8 showed a modest but significant antiviral 
effects in all bioassays and cell systems tested. They did not prevent the proviral integration reaction, 
but negatively interfered with late steps of the HIV-1 life cycle: αRep4E3 blocked the viral genome 
packaging, whereas αRep9A8 altered both virus maturation and genome packaging. Interestingly, 
SupT1 cells stably expressing αRep9A8 acquired long-term resistance to HIV-1, implying that αRep 
proteins can act as antiviral restriction-like factors.
Although highly active antiretroviral therapy (HAART) has significantly reduced the morbidity and mortality 
associated with AIDS, curative therapy has been greatly impaired by the occurrence of drug resistant mutants 
and the persistence of virus in a latent form in reservoirs that resist current HAART1–4. The high mutation rate 
of the human immunodeficiency virus 1 (HIV-1) and the persistence of viruses in tissue sanctuaries impose 
constant efforts to develop new antiviral drugs and new strategies5,6. Alternative strategies include the design of 
genes coding for intracellular factors or interactors with antiviral activity, the genetic manipulation of hemato-
poietic progenitor stem cells7, and the inactivation of proviral DNA in situ by using zinc-finger nucleases (ZFNs), 
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transcription activator-like effector nucleases (TALENS), or the clustered regularly interspaced short palindromic 
repeat/Cas9 (CRISPR) system8. A recent example of the design of novel antivirals based on HIV-1 interactors 
was given by LEDGINs9,10, allosteric inhibitors of integrase (IN) which block the interaction of IN with lens 
epithelium-derived growth factor (LEDGF) or p7511.
Among the anti-HIV therapies using intracellular protein interference, protein-based molecular scaffolds are 
considered as promising antivirals. Antibodies, their derivatives scFv and intrabodies, and single domain anti-
bodies from Camelidae (or nanobodies) are the most commonly used scaffolds to bind protein targets. However, 
the proper folding, stability and biological activity of these molecules require inter- or intra-domain disulfide 
bond formation. This constitutes severe limitations to their development as intracellular antivirals, consider-
ing the reducing environment of the cytoplasm. In order to overcome these limitations, other disulfide-free, 
protein-based molecular scaffolds have been designed, such as artificial ankyrin-repeat proteins (Anks) and the 
ankyrin derivatives DARPINS12–18. Some of these scaffolds are already in preclinical studies for the treatment of 
cancer19, and others, like DARPINS or Anks, have been tested in vitro against HIV-1 infection, and have been 
found to act at the initial step of binding of the virus to its cell surface receptors20, or at post-entry steps21,22.
We have previously designed and characterized two intracellular inhibitors of HIV-1 replication, abbreviated 
2LTRZFP and AnkGAG1D4, which are based on stable modular protein scaffolds. 2LTRZFP is a designed zinc 
finger protein (ZFP) which targets the integrase recognition sequence at the 2-LTR circle junctions, and blocks 
the integration of the HIV-1 cDNA into the host cell genome23,24. AnkGAG1D4 is an artificial ankyrin-repeat 
protein selected as a binder of the N-terminal domain of HIV-1 capsid protein (CA), which was capable of inter-
fering negatively with viral assembly in HIV-1-infected SupT1 cells21,22. Interestingly, the combined expression of 
2LTRZFP and AnkGAG1D4 molecules in HIV-1-infected cells resulted in a significant negative effect on the viral 
replication25.
Another type of molecular scaffold, named alpha-repeat proteins (αRep), were tested as potential antivirals 
against HIV-1 in the present work. The αRep proteins were derived from a natural family of modular proteins 
constituted of alpha-helical repeats, related to HEAT repeats, named after Huntingtin, the elongation factor 3 
(EF3), the protein phosphatase 2A (PP2A), and the yeast kinase TOR126–29. The association of several HEAT 
repeats forms alpha-solenoids of various lengths, which are naturally found in a number of cellular proteins 
involved in intracellular transport and protein-protein interaction26,28. The biophysical properties of αRep pro-
teins are highly favourable to biological and medical applications: (i) αRep proteins are easily expressed in bac-
teria as soluble proteins, implying a properly folded protein; (ii) they are functional in reducing and oxidative 
environments due to their disulfide independent folding, and can be active inside living cells as well as in the 
extracellular milieu; (iii) they are thermostable, with Tm >70 °C; (iv) heat denaturation is reversible and αRep 
proteins refold properly when cooled to 25 °C; (v) aggregation of αRep proteins does not occur at high concen-
trations; (vi) their small size allows the recognition of epitopes of low accessibility, thus increasing the diversity of 
binders for one target28,29. All these biological properties of αRep proteins open a wide range of possibilities for 
their development as diagnostic and therapeutic tools, or for cellular imaging.
In this study, we selected αRep proteins which bind to a region of HIV-1 Pr55Gag polyprotein which encom-
passes the last 21 residues of the capsid (CA21), the SP1 linker and the nucleocapsid (NC) protein with its two 
zinc fingers. This region contained several elements identified as privileged targets for antiviral drugs. (i) SP1, the 
spacer peptide separating the capsid from the nucleocapsid domain, is a 14-residue long, alpha-helical domain 
which is critical for the self-assembly of Pr55Gag, and is the target of betulinic acid-derived assembly inhibi-
tors30–35. (ii) The NC occupies a strategic position in the HIV-1 infectious cycle, as it possesses structural and cata-
lytic properties, and also acts as a nucleic acid chaperone36–40. The multiple functions in which NC is involved41–45, 
as well as its ALIX-mediated role in the virus particle release46,47, justified the inclusion of the NC domain in our 
viral bait.
Two αRep molecules with a high binding activity, αRep4E3 and αRep9A8, were isolated from our screen. 
When the intracellular antiviral functions were assessed in vitro, both αRep proteins showed a modest but signif-
icant inhibitory effect on HIV-1 replication, although interestingly via different mechanisms. αRep4E3 interfered 
negatively with the viral genome packaging, whereas αRep9A8 mainly impaired the proteolytic processing of 
Gag, the step required for the transition of immature particles to infectious virions. Importantly, a SupT1 cell line 
stably expressing the αRep9A8 protein was found to acquire a long-term resistance to HIV-1 infection, with the 
production of noninfectious virus particles at background levels. These results might have significant implications 
in the elaboration of future strategies of anti-HIV-1 cell therapy, based on artificial restriction-like factors.
Results
Selection of αRep binders of the HIV-1 Gag C-terminal domain. Our viral bait, abbreviated CA21-
SP1-NC, spanned from residue L343 to F433 of the Pr55Gag sequence (Fig. 1a). GST-fused CA21-SP1-NC was 
used for the selection of specific binders from a phage-displayed, random library of artificial αRep proteins gen-
erated by combinatorial methods26,27. After three rounds of phage biopanning, 30 individual clones out of an orig-
inal library of ~1.7 × 109 independent bacteriophages, were randomly picked and analyzed by ELISA. Eighteen 
clones were found to react positively with the immobilized bait, and six of them, αRep4D4, -4E3, -4F2, 5A12, 
-5F1 and -9A8, showed a significantly higher signal compared to the twelve other clones. The genes of these six 
αRep were sub-cloned into the pQE-31 expression vector for the production of His-tagged αRep proteins in E. 
coli. After purification by affinity chromatography on Ni2+-column, the six selected αRep proteins were analyzed 
for their binding activity to GST-CA21-SP1-NC in vitro, using an indirect ELISA method. Out of the six clones, 
αRep4E3 and αRep9A8 showed the highest binding reaction with the viral target (not shown), and were there-
fore kept for further characterization. DNA sequencing showed that αRep4E3 and αRep9A8 had in common a 
His-tag at their N-terminus, the flanking N-terminal cap (N-cap) and C-terminal cap (C-cap) sequences, and the 
constant regions of the internal repeat modules (Fig. 1b). αRep4E3 had seven internal repeat modules, 284 amino 
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acids (including N-cap and C-cap) and a molecular mass of 32 kDa, while αRep9A8 had six internal repeats, 253 
amino acids and a molecular mass of 28 kDa (Fig. 2).
Protein pull-down assays. The interaction of αRep4E3 and αRep9A8 with the viral target and the map-
ping of their binding sites on CA21-SP1-NC was investigated using protein pull-down assays. Purified His-tagged 
αRep proteins were incubated with the full-length viral target CA21-SP1-NC, or its carboxy-terminal deletants, 
GST-CA21-SP1-NCΔZF2 (lacking the downstream ZF2), and GST-CA21-SP1 (lacking the whole NC domain; 
see Supplementary Table S1). Protein complexes were isolated on glutathione-coated agarose beads, and ana-
lyzed by SDS-PAGE and Western blotting. Both αRep4E3 and αRep9A8 bound equally well to CA21-SP1-NC, 
but no binding was detectable with the NC-deleted target (Fig. 3a). Deletion of ZF2 significantly decreased the 
binding of both αRep, suggesting an overlap of their binding sites on the Gag target. However, differences were 
observed between the two binding patterns. The amounts of αRep complexed with GST-CA21-SP1-NCΔZF2 
were 5-fold lower for αRep4E3 and 2-fold lower for αRep9A8, compared to their complex with full-length 
GST-CA21-SP1-NC (Fig. 3b). This suggested that the major binding determinants of αRep4E3 mapped to ZF2, 
with minor determinants in ZF1, whereas for αRep9A8, the binding determinants were distributed between the 
ZF1 and the ZF2 domains.
Effects of αRep4E3 and αRep9A8 proteins on HIV-1 VLP assembly and extracellular release: 
quantitative aspects. The effects of the two αRep on HIV-1 assembly were explored using a 
baculovirus-insect cell system of production of HIV-1 virus-like particles (VLPs). In this system, Sf9 cells were 
infected with AcMNPVgag, a recombinant vector derived from the baculovirus AcMNPV (Autographa californica 
Multiple Nuclear Polyhedrosis Virus). AcMNPVgag expresses the full-length, wild-type, N-myristoylated HIV-1 
Gag polyprotein in Sf9 cells, resulting in the assembly and extracellular release of membrane-enveloped VLPs at 
high yields. The high number of particles produced per cell in this heterologous model system of VLP assembly 
and egress, allowed quantitative analyses of morphologically normal VLPs compared to aberrant particles31,33,48–51.
Expression of αRep in insect cells. The αRep4E3 and αRep9A8 genes were fused to the GFP gene and to the 
coding sequence of a six-histidine tag at the C-terminus (Fig. 1c). The coding sequence of an N-myristoylation 
signal22,52 was inserted to the 5′-end of the αRep-GFP genes (Fig. 1c). The resulting genetic constructs were 
transfected into Sf9 cells, and the two Sf9-derived cell lines thus obtained, Sf/(Myr+)αRep4E3-GFP and Sf/
(Myr+)αRep9A8-GFP, stably expressed N-myristoylated (Myr+)αRep4E3-GFP and (Myr+)αRep9A8-GFP 
proteins under the control of the baculoviral OpIE2 promoter (see Supplementary Fig. S1). The aim of the 
Figure 1. Schematic representation of the protein partners. (a) Schematic representation of the viral target, 
spanning residues L343 to F433 of HIV-1 Pr55Gag, with its amino acid sequence (HIV-1LAI isolate) shown 
underneath. Amino acid residues of the SP1 domain are in bold; the cysteine and histidine residues of the zinc 
fingers (ZF1 and ZF2) responsible for the Zn coordinates are in red; the residues of the basic motif separating 
ZF1 and ZF2 are in blue. (b) Three-dimensional model of an αRep molecule. The constant regions N-cap and 
C-cap are shown in red, and the variable region, comprising of four internal alpha-repeats in this particular 
model (n = 4), is in yellow and green. (c) Schematic representation of an αRep-GFP fusion protein, with the 
N-terminus modified to carry a N-myristoylation signal (Myr), and a His-tag at the C-terminus. The respective 
number of amino acids (aa), and molecular weight of αRep4E3, αRep9A8 and GFP domains are indicated in 
kDa.
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N-myristoylation of αRep4E3-GFP and αRep9A8-GFP was to compensate for the difference in cell content 
between the N-myristoylated Pr55Gag polyprotein, expressed at high levels under the control of the strong pol-
yhedrin promoter31,33,48–51, and αRep proteins, expressed at lower levels under the control of the weaker OpIE2 
promoter. Addressing (Myr+)αRep proteins to the plasma membrane was meant to promote the interaction 
between Pr55Gag and αRep proteins at the assembly sites of membrane-enveloped VLPs.
Quantitative effect of (Myr+)αRep4E3 and (Myr+)αRep9A8 on VLP assembly. Control, nonmodified Sf9 cells, 
Sf/(Myr+)αRep4E3-GFP and Sf/(Myr+)αRep9A8-GFP cells were infected with AcMNPVgag, and the amounts of 
VLPs assembled and released into the culture medium were estimated by SDS-PAGE and Western blot analysis of 
pelletable, extracellular Pr55Gag31–33. The intensity of the Pr55Gag band on immunoblots did not radically differ 
between the three samples (data not shown). A quantitative, luciferase-based assay of extracellular VLPs was then 
performed. The principle of this assay resides in the co-packaging of Vpr (and Vpr-fused proteins) with Pr55Gag 
into membrane-enveloped VLPs banding at a density of 1.18. This co-packaging is mediated by the specific inter-
action between the Gag p6 domain and Vpr53,54. The co-expression of the Luciferase-Vpr fusion protein together 
with Pr55Gag by co-infection of Sf9 with the recombinant vectors AcMNPVluc-vpr and AcMNPVgag showed that 
the activity of luciferase co-incorporated with Pr55Gag into VLPs directly reflected the amounts of VLPs released 
in the extracellular medium33.
Control Sf9 cells, Sf/(Myr+)αRep4E3-GFP and Sf/(Myr+)αRep9A8-GFP cells were co-infected with 
AcMNPVgag and AcMNPVluc-vpr, and harvested at 48 hrs pi. Cell lysates and gradient fractions were assayed for 
luciferase activity, and the results of VLP-associated luciferase activity were normalized to the cellular luciferase 
levels33. A peak of luciferase activity was detected at the density of VLPs in all three culture media and at similar 
levels (see Supplementary Fig. S2), which implied minor differences in the amounts of VLPs recovered from the 
different cell lines. This suggested that (Myr+)αRep4E3 and (Myr+)αRep9A8 were not able to completely block 
the assembly and extracellular release of VLPs from AcMNPVgag-infected insect cells.
Effects of αRep4E3 and αRep9A8 on HIV-1 VLP assembly and extracellular release: qualita-
tive aspects. The morphology of VLPs released from αRep-expressing cells were examined under the elec-
tron microscope (EM). From our previous studies48,50,51, membrane-enveloped VLPs released from the plasma 
membrane of AcMNPVgag-infected Sf9 cells appeared as quasi-spherical in shape, and homogeneous in size, 
with a diameter ranging from 110 to 130 nm (Fig. 4). By contrast, Sf/(Myr+)αRep4E3-GFP cells infected with 
Figure 2. Biochemical characteristics of αRep4E3 and αRep9A8. (a,c) Amino acid sequence of αRep4E3 (a) 
and αRep9A8 (c) with the variable residues of the internal repeats shown in red, and constant residues in black. 
(b,d) SDS-PAGE and Coomassie blue staining of affinity-purified, His-tagged αRep proteins (middle lane); 
whole bacterial cell lysates (WCL) are shown on the right lane, and prestained molecular mass markers on the 
left lane.
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Figure 3. Protein pull-down analysis of αRep binding to the Gag target. Aliquots of bacterial cell lysates 
containing the full-length target GST-CA21-SP1-NC, or the carboxy-truncated mutants GST-CA21-SP1-
NC∆ZF2 or GST-CA21-SP1 were incubated with purified αRep4E3 or αRep9A8, and protein complexes, 
isolated on glutathione-coated agarose beads, were analyzed by SDS-PAGE and Western blotting. (a) Blot 
reacted with rabbit anti-αRep antibody, followed by alkaline phosphatase-conjugated goat anti-rabbit IgG 
antibody. Asterisks indicate the immunoreactive bands of αRep4E3 and αRep9A8 proteins. Note the doublet 
band of αRep4E3 protein, suggesting some degree of proteolytic cleavage. (b) Bar graph of the scanning of 
αRep4E3 and αRep9A8 proteins bound to the different viral targets. The level of αRep binding to the full-length 
target GST-CA21-SP1-NC was attributed the 100% value.
Figure 4. Electron microscopy (EM) of VLP assembly and budding from control insect cells. Control Sf9 cells 
were infected with recombinant baculovirus AcMNPVgag expressing the HIV-1 Pr55Gag polyprotein, harvested 
at 48hrs post-infection, and processed for EM observation. Electron micrographs of ultrathin sections of 
cell pellets showing VLPs budding at their surface are presented at low (a), and high magnification (inset, b). 
Abbreviations: EC, extracellular space; PM, plasma membrane; Cy, cytoplasm.
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AcMNPVgag produced a majority of aberrant VLPs, irregular in size and shape, with the frequent occurrence of 
more than one single immature Gag protein core within the same membrane bud (Fig. 5). Likewise, Sf/(Myr+)
αRep9A8-GFP cells infected with AcMNPVgag showed aberrant VLPs (Fig. 6a), or arrested budding morphologies 
at their surface (Fig. 6b). Interestingly, a peculiar type of pattern was observed in (Myr+)αRep9A8-expressing 
cells, consisting of (i) the accumulation of αRep4E3 and αRep9A8 material at the inner leaflet of the plasma 
membrane (Figs 6b and 7a), and (ii) intravesicular budding of VLPs which seemed to be morphologically normal 
(Fig. 7a,b). This suggested that one of the consequences of the (Myr+)αRep9A8-mediated blockade of normal 
VLP budding at the plasma membrane was the redirection of Gag to the internal membranal compartment, and 
the budding of VLPs into intracytoplasmic vesicles.
Quantification of normal and aberrant VLPs released by control Sf9 cells exhibited less than 10% irregular 
particles (9.2%) out of a total number of 869 individual particles examined. However, Sf/(Myr+)αRep4E3-GFP 
cells released more than one third (35%) aberrant VLPs (n = 287), and Sf/(Myr+)αRep9A8-GFP cells about one 
quarter of the total (24.2%; n = 431) (see Supplementary Fig. S3).
Taken together, the results of these analyses suggested that both αRep4E3 and αRep9A8 negatively interfered 
with the assembly of Gag proteins into immature HIV-1 particles. These negative effects were not quantitative, 
as there was no significant difference in the yields of extracellular VLPs compared to control cells. The effects of 
αRep4E3 and αRep9A8 on Gag assembly were qualitative, as shown by the alteration of the structure of VLPs 
and the change in their cellular sites of assembly. In addition, EM analysis suggested two distinct phenotypes for 
αRep4E3 and αRep9A8.
Co-encapsidation of Gag and N-myristoylated αRep proteins into VLPs. Since defective VLP 
assemblies were observed in the presence of αRep4E3 and αRep9A8, we hypothesized that these αRep pro-
teins could be co-packaged with Gag precursor, resulting in altered VLP structure. To test this hypothesis, VLPs 
released from AcMNPVgag-infected Sf/(Myr+)αRep4E3-GFP and Sf/(Myr+)αRep9A8-GFP cells were purified 
by ultracentrifugation, and analyzed by SDS-PAGE and immunoblotting, using anti-Gag antibody to detect 
the Gag polyprotein, and histidine antibody to detect the His-tagged αRep-GFP proteins. An anti-histidine 
immunoreactive protein was detected in both types of VLP samples, at 59 and 55 kDa for αRep4E3-GFP and 
αRep9A8-GFP, respectively. These values corresponded to the respective molecular weights of the GFP-fused 
αRep proteins. The variations in the signal intensity of the 59-kDa and 55-kDa proteins throughout the gradient 
fractions followed the same pattern as that of the Pr55Gag band, with a maximum intensity in fractions of density 
ρ = 1.18 (see Supplementary Fig. S4). This suggested that N-myristoylated αRep4E3-GFP and αRep9A8-GFP 
proteins were able to interact with Pr55Gag at the VLP assembly sites, and to be copackaged with Pr55Gag into 
Figure 5. EM analysis of VLP assembly in αRep4E3-expressing insect cells. Sf/(Myr+)αRep4E3-GFP cells 
were infected with AcMNPVgag, harvested at 48hrs post-infection and processed for EM. Electron micrographs 
of ultrathin sections of cell pellets are shown at low (a), and high magnifications (b-d). EC, extracellular space; 
PM, plasma membrane; Cy, cytoplasm; Nu, nucleoplasm; NM, nuclear membrane.
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membrane-enveloped VLPs of aberrant structure. Of note, no αRep-GFP protein was detected at density 1.18 in 
culture media of Sf/(Myr+)αRep4E3-GFP and Sf/(Myr+)αRep9A8-GFP cells in the absence of the AcMNPVgag 
vector (not shown).
Antiviral activity of αRep4E3 and αRep9A8 proteins in human T-cells challenged with HIV-1. 
The genes encoding αRep4E3-GFP, αRep9A8-GFP and αRep9C2-GFP (GFP-fused irrelevant αRep used as neg-
ative control) were transferred into SupT1 cells. Three αRep-expressing cell lines were successfully established, 
which were referred to as SupT1/αRep4E3-GFP, SupT1/αRep9A8-GFP and SupT1/αRep9C2-GFP cells, respec-
tively (see Supplementary Fig. S5). Of note, the non-N-myristoylated versions of αRep proteins were expressed 
in SupT1 cells to allow them to diffuse and exert their possible antiviral activity in all cell compartments. The cells 
were infected with HIV-1 and the effect of the αRep proteins on HIV-1 infection was assessed by different meth-
ods, as described below. As shown by fluorescence microscopy and flow cytometry, the expression of αRep-GFP 
molecules was maintained at levels close to 100% throughout the time of the viral challenge (21 days; Fig. 8a).
Kinetics of HIV-1 particle production. CAp24-ELISA was used to evaluate the quantities of extracellular viral 
particles released from HIV-1-infected cells at days (D) 3, 7, 14, and 21 pi (Fig. 8b). In control cells, CAp24 was 
detected as early as at D7, with a peak at D14 followed by a decrease at D21 pi (Fig. 8b). However, CAp24 was 
barely detectable in samples from SupT1/αRep4E3-GFP and SupT1/αRep9A8-GFP cell cultures at D14 pi. The 
amounts detected were about 10-fold lower compared to that of control samples, and the CAp24 reached the 
levels observed in control D14-samples only at D21 pi. This indicated that in the cells expressing αRep4E3 and 
αRep9A8, there was a significant delay in the kinetics of HIV-1 replication and viral progeny production.
Extracellular release of HIV-1 genomes. The viral genome copies in the culture media followed the same kinetics 
as CAp24, with a similar delay observed in the presence of αRep4E3 and αRep9A8 (Fig. 8c). The viral load was 
maximal at D14 pi in control samples, and decreased at D21 due to cell apoptosis. In culture media of SupT1/
αRep4E3-GFP and SupT1/αRep9A8-GFP cells, the virus loads slowly increased with time, and reached the max-
imal levels of control samples at D21 pi (Fig. 8c). A net difference between the αRep-induced inhibitory effects 
was observed at D14 pi, with a more pronounced negative effect with αRep4E3 (ca. 8-fold) compared to αRep9A8 
(ca. 2-fold; Fig. 8c).
Figure 6. EM analysis of VLP assembly in αRep9A8-expressing insect cells. Sf/(Myr+)αRep9A8-GFP cells 
were infected with AcMNPVgag, harvested at 48hrs post-infection and processed for EM. The cells presented in 
panel (a) show VLP budding from the plasma membrane. The cell presented in panel (b) shows simultaneous 
VLP budding and abnormal accumulation of Pr55Gag polyprotein at the plasma membrane. IC, intercellular 
space; EC, extracellular space; PM, plasma membrane; Cy, cytoplasm.
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Cytopathic effects of HIV-1 on αRep-expressing SupT1 cells. HIV-1-infected SupT1 cells were maintained in cul-
ture for six weeks. They were monitored by phase microscopy for possible morphological alterations at different 
time points after infection (Fig. 9a). Formation of syncytia and premature cell death were clearly visible in con-
trol cell cultures, in which HIV-1 drastically reduced the proportion of live cells. These cellular alterations were 
delayed in SupT1/αRep4E3-GFP and SupT1/αRep9A8-GFP cultures (Fig. 9a). Cells samples were also collected 
at 3-day intervals, and controlled for cell count and cell viability. As expected, the cell concentration and viability 
decreased rapidly in control SupT1 cell cultures after D7 pi, and there was no more viable cells detected at D21 
pi (Fig. 9b,c). The diminution in living cell numbers was delayed and more progressive in SupT1/αRep4E3-GFP 
and SupT1/αRep9A8-GFP cultures, with a decline starting only after D14 pi. A total cell loss was observed at 
D28 pi in SupT1/αRep4E3-GFP cultures, but a rebound in cell growth was observed after D28 pi in SupT1/
αRep9A8-GFP cultures (Fig. 9b,c).
Proviral DNA status in HIV-1-infected aRep-expressing SupT1 cells. The viral genome integration in HIV-
1-infected SupT1 cells, evaluated at D14 pi by quantitative PCR, showed that Ct values were not significantly 
different between control and αRep-expressing cells (see Supplementary Table S2). This suggested that resident, 
intracellular αRep4E3 and αRep9A8 did not prevent the viral genome integration in SupT1 cells, and that the 
antiviral effects of αRep4E3 and αRep9A8 proteins did not depend on viral integration.
Molecular mechanisms of the αRep4E3- and αRep9A8-mediated antiviral effects. Two major 
parameters influence the infectivity of HIV-1: (i) the degree of proteolytic processing of Pr55Gag which controls 
the transition from immature to condensed, mature core; (ii) the ability of the virus to encapsidate its genomic 
RNA during its morphogenetic process, and thus the genome content of viral particles. It has been commonly 
considered that HIV-1, like most retroviruses, produce large numbers of defective particles lacking all or part 
of the viral genome, and that the infectivity index is usually in the low range of values, ≤1:1,000. However, the 
ratio of infectious to defective HIV-1 particles has been recently re-evaluated to 1:855. Both Gag maturation and 
genome content were assayed in particles produced by αRep-expressing cells infected with HIV-1.
Figure 7. Intravesicular assembly of VLPs in αRep9A8-expressing insect cells. Electron micrographs of 
ultrathin sections of AcMNPVgag-infected Sf/(Myr+)αRep9A8-GFP cells at 48hrs post-infection. The cell 
presented in panel (a) shows the abnormal accumulation of Pr55Gag polyprotein at the plasma membrane, 
and the occurrence of VLPs within intracytoplasmic vesicles. Panels (b,c) present different cell sections at high 
magnification, showing simultaneous intravesicular budding and plasma membrane budding of VLPs. IC, 
intercellular space; EC, extracellular space; PM, plasma membrane; Cy, cytoplasm; IV, intracellular vesicle; Nu, 
nucleoplasm; NM, nuclear membrane.
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Proteolytic maturation of the Pr55Gag precursor. The viral protease-mediated processing of HIV-1 Pr55Gag is 
a sequential and high-order process. The initial cleavage occurs between SP1 and the NC domain, and the sec-
ondary (e.g. MA-CA) and tertiary (e.g. CAp24-SP1) cleavages occur at approximately 10-fold and 400-fold lower 
rates, respectively, than the initial cut56,57. The extent of Gag processing was assayed using HB-8975, a monoclonal 
antibody which recognized the C-terminal epitope DTGHSSQVSQNY only on free MAp17 protein, and not 
on intact Pr55Gag. After cleavage of the MA-CA junction, the exposed epitope can compete with a synthetic 
peptide of the same sequence for binding to HB-8975. The degree of competition in ELISA correlates with the 
extent of MA-CA cleavage, and provided a quantitative evaluation of the degree of Pr55Gag maturation, as shown 
in previous studies58–60. The results indicated that more than 85% viral particles which egressed from control, 
HIV-1-infected cells, and 75% from SupT1/αRep4E3-GFP cells, consisted of mature particles (Fig. 10a). This 
proportion was only 35% for SupT1/αRep9A8-GFP cells (Fig. 10a), suggesting that αRep9A8, but not αRep4E3, 
negatively interfered with the virus maturation.
Viral genome encapsidation. The efficiency of viral genome packaging in the different SupT1 cell lines was 
measured by the ratio of extracellular genome concentration to CAp24 concentration at D14 pi, and the results 
normalized to 25 µg CAp24 per sample, a value which corresponded to 5 × 107 to 7 × 107 infectious particles61,62, 
and 4 × 108 to 6 × 108 total particles55. The results showed that the RNA packaging function was altered in both 
SupT1/αRep4E3-GFP and SupT1/αRep9A8-GFP cell lines, but to different levels: a 10- to 13-fold reduction 
in RNA packaging efficiency was observed in αRep4E3-expressing cells, versus a 3- to 4-fold reduction in 
αRep9A8-expressing cells (Fig. 10b). This implied that the antiviral activity associated with αRep4E3 was pre-
dominantly directed against the viral genome packaging.
Infectivity of the viral progeny. The infectious titer of the viral progeny released from the different SupT1 cell 
lines was determined using Jurkat-GFP cells. This Jurkat T cell-based reporter cell line expresses CD4 and CXCR4 
receptors, and enhanced GFP under the control of the HIV-1 LTR promoter, as a direct and quantitative marker 
of HIV-1 infection and Tat expression63. The results obtained at D10 post-reinfection (Fig. 11, leftmost bars) 
indicated that the infectious titers of viruses which egressed from SupT1/αRep4E3-GFP (1.4%) and SupT1/
αRep9A8-GFP (1.25%) were significantly lower (15- to 17-fold), compared to that from the two control cell lines, 
SupT1 (24%) and SupT1/αRep9C2-GFP cells (19.5%). To evaluate the long-term effects of αRep proteins on 
Figure 8. HIV-1 infection of αRep4E3- and αRep9A8-expressing SupT1 cells. (a) Kinetics of GFP expression. 
Control cells (unmodified SupT1 and SupT1/αRep9C2-GFP) and αRep-GFP-expressing SupT1 cells (SupT1/
αRep4E3-GFP and SupT1/αRep9A8-GFP) were infected with HIV-1 at MOI 1, and monitored by flow 
cytometry from day 3 (D3) to D21 pi. Data presented are mean ± SD of triplicate experiments. (b) Kinetics of 
extracellular release of viral particles. Samples from culture media were collected at different time points pi, as 
indicated, and the levels of CAp24 antigen determined by ELISA. (c) Kinetics of extracellular release of viral 
genomes. Viral RNA yields were determined at D7, D14, and D21 pi in samples of culture media, and results 
expressed as copy number per mL.
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virus titers, the reinfected Jurkat-GFP cells were maintained in culture, and analyzed by flow cytometry at D14 
post-reinfection (Fig. 11, rightmost bars). The virus titers found in SupT1/αRep4E3-GFP samples were in the 
same range of values as those measured in control cells at D10. However, a significant difference (~2-fold) was 
observed between Jurkat-GFP cells reinfected with SupT1/αRep4E3-GFP (27.8%) and SupT1/αRep9A8-GFP 
supernatants (15.4%) at D14 post-reinfection. This indicated that αRep9A8 had a more pronounced negative 
effect on virus infectivity, compared to αRep4E3. Of note, the apparently low infectious titers of culture super-
natants from control SupT1 cells at D14 post-reinfection were due to the massive cell death induced by HIV-1 in 
Jurkat-GFP cells at this time point, and no conclusion could be deduced from these values.
Resident αRep9A8 protein in SupT1 cells conferred resistance to HIV-1 infection. Cells which 
survived from the HIV-1-infected SupT1/αRep9A8-GFP cultures (refer to Fig. 9b,c) were collected at D38 pi, 
and were found to be healthy under the light and fluorescence microscopes (Fig. 12a). Samples from SupT1/
αRep9A8-GFP culture supernatant at D38 pi were then assayed for extracellular virus yields. Viral particles and 
genomes were found in these samples, at concentrations almost equivalent to the values determined at D14 pi 
(Fig. 12b,c). Of note, these values were about 10-fold lower for CAp24 and 3-fold lower for the viral genome cop-
ies, compared to the corresponding parameters in control cell cultures at D14 pi (compare Fig. 12b and Fig. 8b, 
and Fig. 12c and Fig. 8c, respectively). The infectious virus titer of SupT1/αRep9A8-GFP culture supernatants at 
D38 pi was then determined using Jurkat-GFP indicator cells. The results showed that most of the extracellular 
HIV-1 particles released from SupT1/αRep9A8-GFP at this time pi were noninfectious (Fig. 12d).
Figure 9. Cytopathogenicity of HIV-1 in αRep-expressing cells. HIV-1-infected cells were maintained in 
culture for several weeks. Control cell cultures consisted of unmodified SupT1 cells, and of SupT1/αRep9C2-
GFP cells expressing an irrelevant αRep serving as negative control for αRep4E3 and αRep9A8. At different 
time intervals, as indicated, samples were collected and monitored for cell morphology, concentration, and 
viability. (a) Cell morphology, analyzed by phase contrast microscopy. (b) Total cell number per mL. (c) 
Percentage of viable cells. Bars represent the mean ± SD (n = 3).
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Discussion
In recent studies, we established the proof-of-concept that artificial proteins based on repeat motif scaffolds, could 
be used as intracellular antiviral agents, and we demonstrated their therapeutic potential as novel inhibitors of 
HIV-122,23,25. In the present work, we applied this concept to another library of highly thermoresistant protein 
scaffolds, made up of alpha-helicoidal HEAT-like repeats, called αReps26,27,29. The bait used for the screening of 
our phage-displayed αRep library was the HIV-1 Pr55Gag-derived polypeptide CA21SP1-NC. It contained Gag 
determinants essential for achieving the late steps of the HIV-1 life cycle, i.e. the alpha-helical spacer peptide SP1 
and its two flanking domains, the C-terminal domain of the CA protein and the full-length NC domain. Both 
SP130–35 and NC44,45 have been used as targets for antiviral drugs against HIV-1.
Figure 10. Antiviral activity of αRep4E3 and αRep9A8. (a), PR-mediated maturation cleavage of Pr55Gag. 
Control cells (unmodified SupT1 and SupT1/αRep9C2-GFP), and αRep-expressing cells (SupT1/αRep4E3-
GFP and SupT1/αRep9A8-GFP) were infected with HIV-1 at the same MOI, and extracellular media collected. 
After normalization to the CAp24 level (80 µg per sample), the degree of proteolytic cleavage of Pr55Gag 
at the MA-CA junction by the viral protease (PR) was evaluated using an ELISA-based maturation assay. 
The bar graph represents the percentage of cleaved Pr55Gag (mean ± SD; n = 3), estimated from the degree 
of accessibility and reactivity of a Gag-embedded MA epitope towards its specific monoclonal antibody, 
in competition with a free synthetic peptide reproducing its sequence (refer to Materials & Methods). (b), 
Viral genome packaging. Bar graph representing the concentrations of HIV-1 genomes in culture media after 
normalization to CAp24 levels (genome copy number per 25 µg CAp24; mean ± SD; n = 3), and the fold changes 
in culture media of SupT1/αRep4E3-GFP and SupT1/αRep9A8-GFP cells, compared to control cell lines SupT1 
and SupT1/αRep9C2-GFP. (**), P < 0.01; (*), P < 0.05; ns, not significant.
Figure 11. Infectivity of virus progeny released by HIV-1-infected, αRep-expressing SupT1 cells. Control cells 
(unmodified SupT1 and SupT1/αRep9C2-GFP), and αRep-expressing cells (SupT1/αRep4E3-GFP and SupT1/
αRep9A8-GFP) were infected with HIV-1 at the same MOI. Samples from culture media were collected at D14 
pi, and re-inoculated to Tat-dependent, indicator T-cells (Jurkat-GFP cells) after adjustment of the CAp24 levels 
to 15 µg per sample. Jurkat-GFP cells were harvested at D10 and D14 post-reinfection, and GFP-positive cells 
determined by flow cytometry. The results presented in the bar graph (mean ± SD; n = 3) are the percentages of 
GFP-positive, fluorescent cells. (**), P < 0.01; ns, not significant.
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Two αRep molecules, αRep4E3 and αRep9A8, with high binding activity to CA21SP1-NC were isolated from 
our screen. Both were found to exert a modest but significant inhibition on HIV-1, as shown by various biological 
assays. Their antiviral effects were independent of the proviral integration and occurred at the post-integration 
step. Differences were observed in their antiviral properties, as schematized in the model of Fig. 13. The αRep4E3 
showed a marked negative effect on the viral genome packaging, while αRep9A8 interfered negatively with 
Gag maturation and its corollary, virus infectivity. More interesting, αRep9A8-expressing SupT1 cells acquired 
a long-term resistance to HIV-1, as shown by the absence of detectable infectious particles from the culture 
medium of αRep9A8-expressing SupT1 cells collected five weeks after HIV-1 challenge.
The mapping of the binding determinants of αRep4E3 and αRep9A8 on the viral target provided clues to their 
antiviral functions. The antiviral activity of αRep4E3, which mainly concerned the viral genome packaging, was 
consistent with the localization of its major binding site to the downstream zinc finger ZF2. The binding site of 
αRep9A8 spanned a wider NC domain, encompassing both ZF1 and ZF2 with a possible SP1 overlapping. The 
masking of SP1 cleavage sites would explain the negative interference of αRep9A8 with the PR-mediated Gag 
processing.
Since no binding of αRep9A8 to the GST-CA21-SP1 target was detected in our pull-down assays, it could 
be argued that the removal of the NC domain had altered the structure of SP1, and transformed its α-helical 
structure64,65 into a non-structured region. Even though this hypothesis cannot be totally excluded, it was not 
supported by the observation that isolated SP1 peptide in aqueous solution spontaneously folds into an α-helix 
without the aid of the NC, in a concentration-dependent manner. This α-helix forms at millimolar protein con-
centrations, i.e. at values equivalent to those found in virions66–68. Our results suggested that the negative interfer-
ence of αRep9A8 with the viral PR resulted from the masking of the SP1 domain, indirectly via steric hindrance, 
rather than via direct binding.
The binding of αRep9A8 to a relatively large protein domain such as the NC raised a number of issues con-
cerning the structure of the two partners. NMR studies of the three-dimensional structure of the HIV-1 NC pro-
tein have shown that the two ZF form a single folded protein domain characterized by spatial contacts between 
residues belonging to ZF1 and ZF269,70. This globular structure is favoured by a highly conserved proline residue 
(P408 in HIV-1LAI sequence) generating a bend in the linker separating the two ZF, and is stabilized by hydropho-
bic and aromatic interactions between residues belonging to ZF1 and ZF269,70. The binding surface of an αRep 
Figure 12. Resistance of SupT1/αRep9A8 cells to HIV-1 infection. (a), HIV-1-infected SupT1/αRep9A8-
GFP cells were harvested at D38 pi, and cell morphology analyzed by light and fluorescence microscopy 
(magnification 100X). (b–d), Samples from the cell cuture medium collected at D38 pi were assayed for (b) 
CAp24 levels, (c) viral RNA concentration, and (d) infectivity expressed as the percentage of GFP-positive 
Jurkat-GFP reporter cells. Data (mean ± SD; n = 3) were compared with those obtained at D14 pi.
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with six internal repeats, such as αRep9A8, could be estimated to measure between 1,200 and 1,500 Å2, based 
on structural studies of αRep proteins co-crystallized with their target26. Such a surface area would theoretically 
be sufficient to interact with amino acid residues belonging to the two zinc fingers, and even to the adjacent SP1 
linker.
The role of the NC and its two zinc fingers in the temporal control of reverse transcription, viral genome 
replication and packaging have been extensively documented, as well as their contribution to the structure of 
the viral core36–40,71–73. The observed antiviral effects of NC-interactors such as αRep4E3 and αRep9A8 might 
result from the blockage of one or several of these multiple functions. The application of real-time observation 
of fluorescent-tagged Gag in live cells74 to αRep-expressing live SupT1 cells should help us to dissect the kinetics 
and molecular mechanisms of the αRep-mediated antiviral effects, in particular their interference with Gag-RNA 
interaction and Gag assembly. NC also plays a role in the budding and release of HIV-1 particles by recruiting 
proteins of the cellular machinery necessary for viral budding, such as ALIX/AIP146,47. Interestingly however, 
αRep4E3 and αRep9A8 showed no detectable negative effect on virus particle egress.
In terms of antiviral activity, the present study confirmed the feasibility of artificially produce antiviral 
restriction-like factors22,23,25. However, the immunogenenicity of such molecules will need to be assessed before 
envisaging any therapeutic applications. As a preliminary evaluation, we have performed the T-cell epitope pre-
diction search for αRep4E3 and αRep9A8 (http://tools.iedb.org/processing/help/), and found negative MHC 
score values for both of them (unpublished data). The results of our comparative study of αRep4E3 and αRep9A8 
properties suggested that, even though αRep4E3 was more detrimental to viral genome packaging compared 
to αRep9A8, the therapeutic advantage would be in favour of the virus maturation-interfering αRep9A8. In 
addition, the finding that αRep9A8 had the capability to block the production of infectious viral particles, and 
prolong the survival of HIV-1-infected cells, could significantly influence future strategies and choice of antivirals 
in anti-HIV-1 cell therapy.
Methods
Eukaryotic cells. Insect cells. Spodoptera frugiperda (Sf9) cells (Life Technologies) were maintained as 
monolayers at 28 °C in Grace’s insect medium (Life Technologies) supplemented with 15% fetal bovine serum, 
penicillin (100 Units/mL), and streptomycin (100 µg/mL). Mammalian cells. Human embryonic kidney cells 
(HEK293T), obtained from ATCC (Manassas, VA) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies). Human T cells lymphoblastic lymphoma cells SupT1 and Jurkat LTR-GFP cells 
(JLTRG; obtained from the NIH AIDS Reagent Program) were grown in RPMI-1640 medium containing pen-
icillin (100 U/mL), streptomycin (100 µg/mL), 2mM L-glutamine, and 10% FBS (HyClone). All cell lines were 
maintained in a humidified 37 °C incubator containing 5% CO2.
Figure 13. Schematic representation of the distinct antiviral effects of αRep4E3 and αRep9A8 in HIV-1-
infected SupT1 cell. The normal pathway of HIV-1 assembly and egress is represented in (1); the antiviral effects 
of the αRep4E3 and αRep9A8 proteins are displayed in pathways (2) and (3). αRep4E3 (blue symbol) negatively 
interferes with Gag-RNA interaction and genome packaging; αRep9A8 (pink symbol) acts as a virus maturation 
inhibitor. Of note, the model presented in this figure was built by the first author, using a combination of 
elements available from the Servier Medical Art site http://smart.servier.com/. Servier Medical Art by Servier is 
licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/
by/3.0/). As specified, users are free to share, copy and redistribute the material in any medium or format, and to 
adapt, remix, transform, and build upon the material for any purpose, even commercially.
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Bacterial cells and plasmid vectors. XL-1 Blue bacteria (Stratagene) were used as the host strain for generat-
ing the αRep phage library and for phage amplification. M15[pREP4] bacteria (Qiagen) were used to produce 
H6-tagged αRep proteins. E. coli BL21 was used as the host strain for producing GST-tagged proteins of HIV-1 
Gag domains. The pQE-31 plasmid (Qiagen) was used for the production of H6-tagged recombinant αRep pro-
teins. The pGEX-4T1 plasmid (GE Healthcare Life Sciences) was used to produce GST-tagged recombinant pro-
teins at high levels.
Viral vectors. Baculoviral vector. Autographa california multiple nuclear polyhedrosis virus (AcMNPV) 
has been used to construct the recombinant baculoviral vector AcMNPVgag expressing the full-length, 
N-myristoylated wild-type HIV-1 Gag polyprotein, abbreviated Pr55Gag. The production of recombinant 
Pr55Gag and VLPs in AcMNPVgag-infected Sf9 cells have been descrived in detail in previous studies48,50,51.
VSVg-pseudotyped lentiviral vectors. CGW, a HIV-1-based self-inactivating (SIN) lentiviral vector of 
third-generation25,75 was used as the backbone vector to transfer the αRep genes into HEK293T and SupT1 cells. 
HEK293T cells at 70–80% confluence in 10-cm dish were co-transfected with the CGW transfer vector (10 µg/
dish) carrying each one of the GFP-fused αRep genes, the packaging construct pMDLg/pRRE (6.5 µg), pRSV-Rev 
(2.5 µg), and pMD.2 G (3.5 µg). Lentiviral vector particles were harvested from the culture supernatant at 24 and 
48 hrs post-cotransfection. High-titer vector stocks were obtained by ultracentrifugation through a 20% sucrose 
cushion. Viral titers were determined from the percentage of GFP-positive cells in HEK293T cultures infected 
with serial dilution of vector stock samples, at 48 hrs post-infection.
HIV-1 stocks. Replication-competent HIV-1 NL4-3 virus, a X4-tropic strain of HIV-1, was produced by tran-
sient transfection of HEK293T cells by the pNL4-3 plasmid. In brief, monolayers of HEK293T cells at 4 × 106 
cells per 10-cm dish were transfected with 5 µg of the pNL4-3 plasmid using transIT-X2 transfection reagent 
(Mirus Bio, Madison, WI) according to the manufacturer’s protocol. The cells were allowed to grow for 48 hrs. 
HIV-1 virus particles in culture supernatant were then harvested by filtration through sterile syringe filters with 
a 0.45 µm pore size (Millex-HA filter unit; Merck Millipore, Hessen, Germany). HIV-1 stock was aliquoted and 
kept frozen at −80 °C. Virus particle titers were determined by conventional ELISA for CAp24-antigen, using 
the Genscreen ULTRA HIV Ag-Ab assay (Bio-Rad, Marnes-la-Coquette, France). Viral loads were determined 
using the COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Test v2.0 (Roche Molecular Systems, Branchburg, NJ).
Generation of HIV-1 target proteins. Our viral targets consisted of various glutathione-S-transferase 
(GST)-fused polyproteins derived from the HIV-1 GagPr55 precursor (LAI isolate). GST-CA21-SP1-NC included 
the 21 amino acids of the C-terminal domain of the capsid protein (CA), fused to the SP1 linker and the whole 
nucleocapsid (NC) domain, encompassing its two zinc fingers (ZF) until residue F433 (Fig. 1a). A panel of 
C-truncated mutants of GST-CA21SP1-NC were constructed by PCR amplification, using specific oligonucleotide 
primers (see Supplementary Table S1). The amplification products were purified by GeneJET PCR Purification 
kit, and a first step gene cloning was performed using InsTAclone PCR cloning kit (ThermoFisher Scientific, 
Waltham, MA). XL-1 Blue competent cells were transformed by the ligation products, and colonies were picked 
for PCR amplification, restriction enzyme analysis using BamHI and XhoI, followed by DNA sequencing. Each 
construct was isolated from the pTZ57R/T vector and transferred to pGEX-GST expression vector using the same 
restriction sites, BamHI and XhoI. The step of clonal identification was performed as previously described21,22.
Three pGEX-GST-gag plasmids were constructed: (i) pGEX-GST-CA21-SP1-NC; (ii) pGEX-GST- 
CA21-SP1-NCΔZF2; and (iii) pGEX-GST-CA21-SP1. BL21 cells were used for recombinant Gag protein production. 
BL-21 harboring each of the recombinant pGEX-GST-gag plasmids were cultured in 200 mL LB broth containing 
100 µg/mL ampicillin and 1% (w/v) glucose, at 37 °C with shaking. When OD600 reached 0.8, protein expression was 
induced by addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and maintained in culture at 30 °C 
overnight with shaking. Cells were pelleted by centrifugation at 1,200 × g for 30 min at 4 °C. Cell pellets were resus-
pended in PBS containing a cocktail of protease inhibitors (Roche Diagnostics GmbH), then lysed by sonication. 
Soluble proteins were purified by affinity chromatography on glutathione-agarose gel (ThermoFisher Scientific), 
following the protocol of the manufacturer, and analyzed by SDS-PAGE and Western blotting.
Screening of the αRep library on the viral target. The construction of the αRep phage library 2.1 has 
been described in a previous study27. In brief, the αRep library was constructed by polymerization of synthetic 
microgenes corresponding to individual HEAT-like repeats, and the αRep proteins were expressed at the surface 
of M13-derived filamentous phages (phage display). In terms of diversity, our αRep library is estimated to contain 
1.7 × 109 independent clones.
For the αRep library screening, purified GST-CA21SP1-NC protein which represented our viral target was 
diluted at 5 µg/mL in coating buffer (TBST: 20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20) was 
immobilized on glutathione-coated microtiter ELISA plate (ThermoFisher Scientific) by incubation overnight 
at 4 °C in a moisture chamber. The coated wells were washed four times with TBST, and saturated with blocking 
solution (2% BSA in TBST; 200 µL/well) for 1 hr, after which an aliquot of the phage library was added to the 
GST-CA21SP1-NC coated wells, and incubated at room temperature (RT) for 1 hr with shaking. Several washes of 
the wells were then performed with TBST, and bound phages were eluted by three successive rounds of adsorp-
tion/elution. Phage elution was performed by acidic solution (0.1 M glycine-HCl buffer, pH 2.5) in the first two 
rounds. The last phage elution consisted of specific ligand elution76,77, by using a large excess of GST-CA21SP1-NC 
as the competitor. The population of αRep-displayed phages eluted from the GST-CA21SP1-NC bait was then 
amplified and subcloned in XL-1 Blue cells, as described for ankyrin scaffolds21,22.
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Individual phage clones were selected and amplified as previously described21,22, and their respective 
binding activity towards the GST-CA21SP1-NC target was determined by ELISA. 100 µL-aliquots of purified 
GST-CA21SP1-NC (5 µg protein/mL) were diluted in PBS and dispensed into the wells of a glutathione-coated 
microtiter plate, then incubated overnight at 4 °C. The coated plate was washed four times with TBST, then 
blocked with TBST-BSA (200 µL per well) at RT for 1 hr with shaking. After a washing step, 100 µL-aliquots of 
each phage culture supernatant were added to the wells and incubated at RT for 1 hr, followed by HRP-conjugated 
mouse anti-M13 (GE Healthcare Life Sciences) diluted to 1:5,000 in TBST-BSA (100 µL-aliquot per well), and 
incubation proceeded at RT for an extra 1 hr. The wells were washed again, prior to the addition of 100 µL 
SureBlue™ TMB Microwell Substrate (KPL, Gaithersburg, MD). Reaction was stopped with 1 N HCl, and absorb-
ance measured at 450 nm. Phage clones showing a high binding activity towards the immobilized target were 
sequenced and kept for cytoplasmic expression of individual αRep proteins.
Expression and purification of αRep proteins. The αRep genes corresponding to strong binders to the 
GST-CA21-SP1-NC target were sub-cloned in pQE-31 plasmids, and used for transforming the bacterial strain 
M15[pREP4] strain, as previously described21,22. M15[pREP4] cells harboring the pQE31-αRep plasmids were 
grown at 37 °C in LB broth supplemented with ampicillin (100 µg/mL), kanamycin (25 µg/mL), and 1% (w:v) glu-
cose with shaking. When absorbance at 600 nm reached 0.8, the αRep protein expression was induced by addition 
of 1 mM IPTG, and cells further incubated for 4 hrs at 30 °C with shaking. Bacteria were pelleted by centrifugation 
(1,200 × g for 30 min at 4 °C), and bacterial cell pellets resuspended in PBS containing a cocktail of protease inhib-
itors (Roche Diagnostics GmbH), then lysed by sonication. Bacterial cells lysates were clarified by centrifugation 
at 15,000 × g for 30 min at 4 °C. Soluble, H6-tagged recombinant αRep proteins were purified by affinity chroma-
tography on HisTrap columns (GE Healthcare Life Sciences), and analyzed by SDS-PAGE and Western blotting.
Protein pull-down assays. E. coli BL21 cells were transformed with plasmids pGEX-4T1 harboring the 
genes encoding the GST-CA21-SP1-NC, GST-CA21-SP1-NC∆ZF2, and GST-CA21-SP1 proteins, and bacterial 
cells cultured in Terrific broth (TR) medium supplemented with ampicillin (100 µg/mL), and glucose (1%; w/v) 
at 37 °C with shaking. When the OD600 of the cultures reached 0.8, protein expression was induced by addition of 
0.1 mM IPTG, and the culture was further maintained at 30 °C for 16 hrs with shaking. Bacterial cells were then 
pelleted by centrifugation at 1,200 × g at 4 °C for 30 min, resuspended in PBS containing a cocktail of protease 
inhibitors (Roche Diagnostics GmbH), and sonicated. After clarification by centrifugation (15,000 × g at 4 °C, for 
30 min), aliquots of supernatants containing GST-CA21-SP1-NC, GST-CA21-SP1-NC∆ZF2, or GST-CA21-SP1 
were incubated with purified His-tagged αRep4E3 or αRep9A8 protein (300 µg) in PBS-0.01% Tween-20 
(1 ml total volume), for 2 hrs at RT with shaking. Aliquots (20 µl) of glutathione-coated agarose beads (Pierce 
Glutathione Agarose; ThermoScientific, Waltham, MA) were then added to the reaction mixture, and further 
incubated for 1 hr at RT with shaking. Beads were centrifuged at low speed, washed 4 times with 0.05% Tween-20 
in PBS, and resuspended and heat-denatured in SDS-PAGE loading buffer for Western blot analysis.
SDS-PAGE and Western blotting. Samples normalized to equal amounts of total protein were separated 
by electrophoresis in SDS-containing 12%- or 15%-polyacrylamide gel. Gels were stained with PageBlueTM pro-
tein staining solution (ThermoFisher Scientific), or used for Western blotting (WB). For WB, proteins sepa-
rated on SDS-gels were electrically transferred to PVDF membrane (GE Healthcare, UK). After blocking with 5% 
skimmed milk in TBST, the PVDF membranes were incubated with various primary and secondary antibodies. 
GST-tagged proteins were detected using rabbit anti-GST antibody (Applied Biological Materials Inc., Richmond, 
Canada [ABM]). Gag proteins were detected using rabbit anti-Pr55Gag antibody (laboratory-made31–33). αRep 
proteins were detected using mouse monoclonal anti-H6 tag (ABM), in the conditions recommended by the man-
ufacturer, or rabbit polyclonal anti-αRep protein (laboratory-made). Secondary antibodies consisted of HRP- or 
phosphatase-conjugated goat anti-mouse or anti-rabbit IgG antibody (KPL, Gaithersburg, MD), followed by spe-
cific chromogen reaction and color development. The protein bands on blots were scanned using the Photo Scan 
Lite application and the average relative band intensity values were obtained using Image Studio Lite Software 
Version 5.2.5.
Construction of Sf9-derived cell lines stably expressing N-myristoylated αRep pro-
teins. The integrative plasmid pIB/V5-His-TOPO vector (Life Technologies) was used for stable expression 
of GFP-tagged and N-myristoylated αRep proteins in Sf9 cells, under the control of the OplE2 promoter. The 
sequence coding for a N-myristoylation signal22,25 was inserted at the 5′-end of the αRep-GFP genes to obtain 
N-myristoylated recombinant proteins, abbreviated (Myr+)αRep-GFP (Fig. 1c). Sf9 cells were transfected with 
the pIBV5-His-TOPO-based vectors (2.5 µg/106 cells), using the DOTAP Liposomal Transfection Reagent (Roche 
Diagnostics GmbH). Transfected cells were maintained in complete Grace’s insect cell medium containing blas-
ticidin (ThermoFisher Scientific) at 100 µg/mL. Two Sf9-derived cell lines were thus generated, referred to as Sf/
(Myr+)4E3-GFP and Sf/(Myr+)9A8-GFP (see Supplementary Fig. S1). The expression of these proteins was 
monitored by fluorescence microscopy, and confirmed by SDS-PAGE and Western blot analysis using rabbit 
polyclonal anti-αRep antibody (laboratory-made).
Isolation of extracellular HIV-1 virus-like particles (VLPs). Sf9 cells were infected with AcMNPVgag 
at an input multiplicity of 10 PFU/cell (MOI 10). Cells were harvested at 48 hrs postinfection (pi), and the cul-
ture supernatants were clarified by low-speed centrifugation. VLPs were recovered from the clarified superna-
tants using a two-step procedure comprising (i) a sucrose-step gradient centrifugation, followed by (ii) isopycnic 
ultracentrifugation31–33,78. In step (i), VLPs were pelleted through a sucrose cushion (20%, w:v, in TNE buffer; 
TNE: 100 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM Na2EDTA) at 30 krpm for 1 hr at 15 °C in a Beckman SW55 
rotor. For step (ii), pelleted VLPs were gently resuspended in 0.20–0.25 mL PBS, and centrifuged in a linear 
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sucrose-D2O gradient. Linear gradients (10-mL total volume, 30–50%, w:v) were centrifuged for 18 hrs at 28 
krpm in a Beckman SW41 rotor. The 50% sucrose solution was prepared in D2O buffered to pH 7.2 with NaOH, 
and the 30% sucrose solution was prepared in 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5.7 mM Na2EDTA. 
Aliquots of 0.5 mL were collected from the top, and fractions analyzed for protein content by SDS-PAGE and 
immunoblotting, and by luciferase assays, as detailed below.
Luciferase-based quantitative assay for HIV-1 Gag assembly and extracellular release of 
VLPs. The co-expression of the Luc-Vpr fusion protein by AcMNPVLucVpr results in the incorporation 
of Luc-Vpr into Gag VLPs via the interaction of Vpr with the Gag p6 domain33. The levels of luciferase activ-
ity present in the pelletable fraction from the culture supernatant represented the amount of VLPs released. 
Aliquots (106) of Sf9 (control cells), Sf/(Myr+)4E3-GFP and Sf/(Myr+)9A8-GFP cells were co-infected with 
two recombinant baculoviruses, AcMNPVgag and AcMNPVLucVpr, at equal multiplicity of infection each (MOI 
10). Co-infected cells were harvested at 48 hrs pi, and the amounts of extracellular VLPs released in the culture 
medium were quantitated using luciferase assays. VLPs were pelleted and lysed in KDT buffer (KDT: 0.1 M potas-
sium phosphate buffer, pH 7.8, 1 mM DTT, containing 0.2% Triton × 100) for 30 min at 37 °C with vortexing every 
10 min. The VLP-associated luciferase activity was measured using luciferin-ATP substrate (VivaGlo™ Luciferin, 
Promega) and the Lumat LB-9501 luminometer (Berthold Technologies, Bad Wildbad, Germany), as previously 
described33, and results expressed as relative light units (RLU) per μg protein. In order to correct for possible 
variations in the cellular expression of LucVpr, the values obtained with VLPs were normalized to the luciferase 
activity measured in the corresponding cell lysates, also expressed as RLU/μg protein.
Electron microscopy. Control Sf9 cells, Sf/(Myr+)4E3-GFP and Sf/(Myr+)9A8-GFP cells were infected 
with AcMNPVgag at MOI 10, harvested at 48 hrs post-infection, and processed for EM observation as described 
in previous studies31–33,48. Cells were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.5, post-fixed 
with osmium tetroxide (2% in H2O) and treated with 0.5% tannic acid solution in H2O. The specimens were dehy-
drated and embedded in Epon (Epon-812; Fulham, Latham, NY). Ultrathin sections were stained with 2.6% alka-
line lead citrate and 0.5% uranyl acetate in 50% ethanol, and poststained with 0.5% uranyl acetate solution in H2O. 
Grids were examined under a Jeol JEM-1400 electron microscope, equipped with an ORIUS™ digitalized camera 
(Gatan France, 78113-Grandchamp). For statistical EM analyses, a minimum of 50 grid squares containing 10 to 
20 cell sections each were examined for counting VLPs budding at the cell surface, released in the external milieu 
or remaining in intracellular compartments31–33,48.
Flow cytometry. The efficacy of cell transfection or transduction by lentiviral vectors was evaluated by flow 
cytometry. Cell samples were harvested at 48 hrs post-transfection or transduction. Cells were washed once 
with PBS, then with PBS containing 1% FBS-0.02% NaN3. After the washing steps, the cells were resuspended 
in 1% paraformaldehyde in PBS and analyzed by flow cytometry, using a BD AccuriTMC6 flow cytometer (BD 
Biosciences).
Construction of SupT1 cell lines stably expressing αRep proteins. VSVg-pseudotyped CGW vec-
tors harboring the genes encoding the non-N-myristoylated version of αRep4E3-GFP or αRep9A8-GFP proteins 
were produced in HEK293T cells. As negative control, an irrelevant, GFP-fused αRep (αRep9C2-GFP) was also 
inserted into CGW. Aliquots of SupT1 cells were transduced with VSVg-pseudotyped CGW-αRep-GFP vectors 
at MOI 1, using spinoculation at 2,500 × g and 32 °C for 2 hrs in growth medium containing Polybrene (8 µg/
mL; Sigma-Aldrich, St. Louis, MO). At 16 hrs post-transduction, cells were washed 5 times with serum-free 
RPMI, and further incubated at 37 °C and 5% CO2 in fresh C-RPMI supplemented with FBS (10%), penicillin 
(100 U/mL) and streptomycin (100 µg/mL). The cells were then divided every 3 days and resuspended in fresh 
growth medium. Three stable cell lines, referred to as SupT1/αRep4E3-GFP, SupT1/αRep9A8-GFP and SupT1/
αRep9C2-GFP cells, respectively, were isolated, and monitored by fluorescence microscopy and flow cytometry 
(BD AccuriTM C6, BD Biosciences).
Antiviral activity of αRep proteins in HIV-1-infected SupT1 cells. Control SupT1 cells and SupT1 
cells stably expressing αRep4E3, αRep9A8 or αRep9C2 were maintained in growth medium for at least 4 weeks 
before incubation with HIV-1 NL4-3 virus inoculum at MOI 1 for 16 hrs. After rinsing with serum-free medium, 
the cells were resuspended in fresh growth medium, and maintained in culture for several weeks. HIV-1 par-
ticle yields were determined in the cell culture supernatants collected at 3-day intervals, using CAp24-ELISA 
(Bio-Rad, Marnes-la-Coquette, France), and viral genome copy numbers were assayed using the COBAS® 
AmpliPrep/COBAS® TaqMan HIV-1 Test v2.0 (Roche Molecular Systems, Branchburg, NJ).
The evaluation of viral genome integration could not be performed by using conventional Alu-Gag PCR assays 
on αRep-expressing SupT1 cells. These stable cell lines were generated by using the third-generation lentiviral 
vectors, which contain part of the U5 region required for the integration of the αRep gene into the cell chromo-
some. As a consequence, this region would give a positive signal in Alu-Gag PCR assays, even with noninfected 
cells. To avoid this drawback, viral genome integration was evaluated using SYBR green-based qRT-PCR assays 
performed on high molecular weight DNA isolated from infected cell lysates, with a pair of primers specific to 
an internal sequence of the pol-prt gene (see Supplementary Table S2). The kit used in these assays was the High 
Pure PCR Template Preparation Kit (Roche Product No. 11796828001), which has been developed to recover 
high molecular weight DNA from cellular genomic DNA, ranging from 30 to 50 kbp and free of contaminations 
with unintegrated viral cDNA.
The cell viability was evaluated using Trypan blue dye exclusion assays and the Countess™ Automated Cell 
Counter (Invitrogen, Thermo Fisher Scientific).
www.nature.com/scientificreports/
17SCIenTIFIC REPoRTS | 7: 16335  | DOI:10.1038/s41598-017-16451-w
ELISA-based HIV-1 Gag processing assay. The ELISA-based assay used to quantitate the extent of Gag 
processing relied on HB-8975, an anti-matrix (MA) monoclonal antibody issued from the hybridoma clone 
MHSVM33C9/ATCC HB-8975, and obtained from the American Type Culture Collection (ATCC, Manassas, 
VA). HB-8975 fails to react with its epitope (DTGHSSQVSQNY) located immediately upstream to the MA-CA 
junction when the MA domain is embedded in the Pr55Gag polyprotein precursor. After PR-mediated cleavage 
of the MA-CA junction, this epitope becomes fully exposed and accessible to HB-8975, and can compete with a 
free synthetic peptide mimicking its amino acid sequence. The degree of competition in ELISA correlates with 
the extent of MA-CA cut, and provides a quantitative evaluation of the degree of Pr55Gag maturation, as shown 
in previous studies58–60.
Microtiter plates were coated with 100 µL anti-MA HB-8975, diluted at 5 µg/mL in coating buffer (1 M 
NaHCO3 pH 9.6), and left overnight at 4 °C in a moisture chamber. Wells were washed 3 times with PBS-T, and 
incubated with 200 µL blocking solution (2% BSA in PBS) at RT for 1 hr to prevent non-specific binding. Next, 
60 µL-aliquots of cell culture medium, normalized to the same CAp24 titer (80 µg/mL), were pre-incubated with 
Triton X-100 (1% final concentration) and 10 ng/mL biotinylated synthetic MAp17 C-terminal peptide at RT for 
10 min. The mixtures were then added to the wells and incubation proceeded for 1hr. The binding reaction was 
revealed by incubation with HPR-conjugated streptavidin at RT for 1 hr, followed by addition of 100 µL-aliquots 
of TMB microwell peroxidase substrate. The reaction was stopped with 1 N HCl, and the optical density measured 
at 450 nm.
Infectivity assays. Infectious titers were determined using JLTRG cells, a CD4/CXCR4-expressing Jurkat 
T cell-based reporter cell line, which harbors the enhanced GFP gene under the control of the HIV-1 LTR pro-
moter. JLTRG cells (referred to as Jurkat-GFP cells in the present study) are Tat-dependent indicator T-cells 
which express GFP upon infection with HIV-163. Samples from culture supernatants were adjusted to equal 
amounts of CAp24 (15 µg/mL) by dilution into fresh C-RPMI. Jurkat-GFP cells were seeded at 2.5 × 105 cells/
well in 96-well culture plate containing 8 µg/mL Polybrene (Sigma-Aldrich, St. Louis, MO). 100 μL-aliquots of the 
CAp24-normalized culture supernatants were added to the wells, and further incubated at 37 °C and 5% CO2 for 
16 hrs. At 16 hrs pi, 100 μL-aliquots of fresh C-RPMI was added to the wells. Jurkat-GFP cells were harvested at 
D14 pi and assayed for GFP-positivity by flow cytometry63,79–81.
Statistical analysis. Unless otherwise stated, results were expressed as mean ± SD of n experiments, 
using the GraphPad Prism version 6.01 for Windows (www.graphpad.com; GraphPad Software, La Jolla, CA). 
Differences were considered statistically significant when P < 0.05.
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